$DHR

Generating a unique summary for DHR…

AI-generated for information only — not investment advice.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Institutions hold 84.50% · insiders 10.96% · 2,866 institutions

Consensus score 1.50 (1 = strong buy, 5 = sell) · mean target 229.09

• Wells FargoEqual-Weightmain2026-07-22
• TD CowenBuymain2026-07-22
• StifelBuymain2026-07-22
• GuggenheimBuymain2026-07-22
• RBC CapitalOutperformmain2026-07-22
• Evercore ISI GroupOutperformmain2026-07-06
• Piper SandlerNeutralinit2026-06-11
• HSBCBuymain2026-06-03
• CitigroupNeutraldown2026-05-27
• Morgan StanleyOverweightmain2026-04-23

Next report: 2026-10-20

• 8-KCorporate Changes & Voting Matters2026-08-03Open
• 8-KCorporate Changes & Voting Matters2026-07-21Open
• 11-KAnnual report of employee stock purchase2026-06-16Open
• S-8Offering Registrations2026-06-09Open
• 8-KCorporate Changes & Voting Matters2026-06-03Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-12Open
• 8-KCorporate Changes & Voting Matters2026-05-07Open
• 8-KCorporate Changes & Voting Matters2026-04-29Open
• 10-QPeriodic Financial Reports2026-04-21Open
• 8-KCorporate Changes & Voting Matters2026-04-17Open

• Abcam and Genedata Collaborate to Accelerate AI-Driven Antibody Development at Global Scale

  Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced an expanded collaboration with Abcam, a global provider of validated antibodies and assay solutions. By deploying Genedata Biologics® across Abcam's global R&D organization, the two Danaher companies are working together to strengthen antibody development capabilities, unlock the value of scientific data, and accelerate AI-enabled innovation.

  Thu, 03 Sep 2026 12:30:00 +0000

• Is Danaher Stock Underperforming the Nasdaq?

  Danaher has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

  Mon, 31 Aug 2026 14:34:20 +0000

• Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

  DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

  Tue, 25 Aug 2026 14:04:00 +0000

• Masimo Receives FDA 510(k) Clearance for Root® with LiDCO® and the Masimo LiDCO Sensor to Provide Continuous Oxygen Delivery (DO₂)

  Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced FDA 510(k) clearance for the Masimo Root® with LiDCO® hemodynamic monitoring solution, including the Masimo LiDCO sensor. This comprehensive solution provides the unique ability to continuously monitor and trend oxygen delivery (DO₂) that reflects changes in both cardiac output and arterial oxygen content.

  Tue, 25 Aug 2026 13:00:00 +0000

• BRC Therapeutics Appoints Biopharma Veteran Chandra Ramanathan as Executive Vice President of Commercialization and Strategy

  BRC Therapeutics (BRC), a clinical-stage pharmaceutical company developing multimodal cannabinoid therapeutics for neurological and inflammatory conditions, today announced the appointment of Chandra Ramanathan, Ph.D., M.B.A., as Executive Vice President of Commercialization and Strategy. Ramanathan brings more than 30 years of biopharmaceutical leadership spanning drug development, global product launches, commercialization, and external innovation to BRC as the company advances its pipeline an

  Mon, 24 Aug 2026 15:00:00 +0000

• 1 Profitable Stock with Exciting Potential and 2 We Brush Off

  Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

  Mon, 24 Aug 2026 09:21:36 +0000

• Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

  Healthcare investors often face a difficult decision when choosing between companies with very different paths to growth. Some businesses are emerging from temporary industry slowdowns, while others continue compounding through durable competitive advantages. Danaher Corporation (NYSE:DHR) and Intuitive Surgical (NASDAQ:ISRG) illustrate that contrast perfectly. Danaher (NYSE:DHR) is beginning to benefit from improving life sciences spending […]

  Sun, 23 Aug 2026 22:21:35 +0000

• Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?

  Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.

  Fri, 04 Sep 2026 11:49:00 +0000